{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:17:01Z","timestamp":1763018221013},"reference-count":45,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,8,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Proteasome inhibition results in extensive immunomodulatory effects that augment natural killer cell cytotoxicity and inhibit aspects of T-cell, B-cell, and dendritic cell function. We performed a phase 2 study that examined the effects of ixazomib for graft-versus-host disease (GVHD) prophylaxis (up to 12 cycles) with posttransplant cyclophosphamide and tacrolimus after standard nonmyeloablative haploidentical donor transplantation (HIDT). Ixazomib was started on day +5 (4 mg on days 1, 8, and 15 of a 28-day cycle), with dose reductions allowed in future cycles for toxicity. All patients received peripheral blood stem cells. Twenty-five patients were enrolled with a median age of 62 years (range, 35-77 years) who had acute leukemia (4), myelodysplastic syndrome (7), non-Hodgkin lymphoma\/Hodgkin lymphoma\/chronic lymphocytic leukemia (8), and myeloma (6). The hematopoietic cell transplant comorbidity index was \u22653 in 68% of the patients. After a median follow-up of 33.5 months, the cumulative incidence of relapse\/progression at 1 year was 24% and 44% at 3 years, which failed to meet the statistically predefined goal of decreasing 1-year risk of relapse. Engraftment occurred in all patients with no secondary graft failure, and 3-year nonrelapse mortality (NRM) was 12%. Cumulative incidence of grade 3 to 4 acute GVHD was 8%, whereas moderate-to-severe chronic GVHD occurred in 19%. Nineteen patients survive with an estimated 1-year overall survival (OS) of 84% and 3-year OS of 74%. Hematologic and cutaneous toxicities were common but manageable. The substitution of ixazomib for mycophenolate mofetil (MMF) post-HIDT results in reliable engraftment, comparable rates of clinically significant GVHD, relapse and NRM, and favorable OS. This trial was registered at www.clinicaltrials.gov as # NCT02169791.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001958","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T17:48:29Z","timestamp":1597081709000},"page":"3669-3676","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant"],"prefix":"10.1182","volume":"4","author":[{"given":"Scott R.","family":"Solomon","sequence":"first","affiliation":[{"name":"Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health, University of Texas, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacey","family":"Brown","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelin C.","family":"Jackson","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Kent","family":"Holland","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence E.","family":"Morris","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, GA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"issue":"10","key":"2020081011342818600_B1","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.2012.44.3523","article-title":"T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation","volume":"31","author":"Bashey","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020081011342818600_B2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3324\/haematol.2017.187450","article-title":"Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT","volume":"104","author":"Brissot","year":"2019","journal-title":"Haematologica"},{"issue":"8","key":"2020081011342818600_B3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2020081011342818600_B4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020081011342818600_B5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2020081011342818600_B6","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020081011342818600_B7","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.bbmt.2013.05.011","article-title":"Effects of bortezomib on the immune system: a focus on immune regulation","volume":"19","author":"Mohty","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020081011342818600_B8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","article-title":"Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition","volume":"180","author":"Hallett","year":"2008","journal-title":"J Immunol"},{"issue":"6","key":"2020081011342818600_B9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.blre.2013.10.002","article-title":"Targeting the ubiquitin proteasome system in haematological malignancies","volume":"27","author":"Crawford","year":"2013","journal-title":"Blood Rev"},{"issue":"24","key":"2020081011342818600_B10","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/0008-5472.CAN-15-0794","article-title":"Bortezomib improves adoptive T-cell therapy by sensitizing cancer cells to FasL cytotoxicity","volume":"75","author":"Shanker","year":"2015","journal-title":"Cancer Res"},{"issue":"21","key":"2020081011342818600_B11","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2020081011342818600_B12","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/j.bbmt.2015.05.027","article-title":"A bortezomib-based regimen offers promising survival and graft-versus-host disease prophylaxis in myeloablative HLA-mismatched and unrelated donor transplantation: a phase II trial","volume":"21","author":"Koreth","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2020081011342818600_B13","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1200\/JCO.2012.42.0984","article-title":"Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation","volume":"30","author":"Koreth","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020081011342818600_B14","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"2020081011342818600_B15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbmt.2016.11.015","article-title":"Post-transplantation cyclophosphamide and ixazomib combination rescues mice subjected to experimental graft-versus-host disease and is superior to either agent alone","volume":"23","author":"Al-Homsi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020081011342818600_B16","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020081011342818600_B17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020081011342818600_B18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"27","key":"2020081011342818600_B19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020081011342818600_B20","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"issue":"12","key":"2020081011342818600_B21","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"2020081011342818600_B22","first-page":"360","article-title":"Nonparametric estimation from incomplete observations","volume":"84","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"10","key":"2020081011342818600_B23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/sj.bmt.1703260","article-title":"Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis","volume":"28","author":"Klein","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"2020081011342818600_B24","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.4049\/jimmunol.1801489","article-title":"Impact of KIR\/HLA incompatibilities on NK cell reconstitution and clinical outcome after T cell-replete haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide","volume":"202","author":"Willem","year":"2019","journal-title":"J Immunol"},{"issue":"3","key":"2020081011342818600_B25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbmt.2017.11.042","article-title":"Killer cell immunoglobulin-like receptor-ligand mismatch in donor versus recipient direction provides better graft-versus-tumor effect in patients with hematologic malignancies undergoing allogeneic T cell-replete haploidentical transplantation followed by post-transplant cyclophosphamide","volume":"24","author":"Wanquet","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020081011342818600_B26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbmt.2018.01.013","article-title":"Selecting the best donor for haploidentical transplant: impact of HLA, killer cell immunoglobulin-like receptor genotyping, and other clinical variables","volume":"24","author":"Solomon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020081011342818600_B27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.seminhematol.2019.03.005","article-title":"Immune reconstitution after T-cell replete HLA-haploidentical transplantation","volume":"56","author":"McCurdy","year":"2019","journal-title":"Semin Hematol"},{"issue":"11","key":"2020081011342818600_B28","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/TP.0b013e3182911739","article-title":"Proteasome inhibition profoundly affects activated human B cells","volume":"95","author":"Mulder","year":"2013","journal-title":"Transplantation"},{"issue":"10","key":"2020081011342818600_B29","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood-2014-02-554279","article-title":"Treatment of chronic graft-versus-host disease with bortezomib","volume":"124","author":"Pai","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2020081011342818600_B30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.exphem.2016.05.005","article-title":"Bortezomib for the prevention and treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"44","author":"Al-Homsi","year":"2016","journal-title":"Exp Hematol"},{"issue":"3","key":"2020081011342818600_B31","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9","key":"2020081011342818600_B32","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood-2004-11-4526","article-title":"Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity","volume":"106","author":"Sun","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2020081011342818600_B33","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.bbmt.2017.05.024","article-title":"Calcineurin and mTOR inhibitor-free post-transplantation cyclophosphamide and bortezomib combination for graft-versus-host disease prevention after peripheral blood allogeneic hematopoietic stem cell transplantation: a phase I\/II study","volume":"23","author":"Al-Homsi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020081011342818600_B34","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.4049\/jimmunol.0901596","article-title":"The proteasome inhibitor bortezomib enhances the susceptibility to viral infection","volume":"183","author":"Basler","year":"2009","journal-title":"J Immunol"},{"key":"2020081011342818600_B35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fmicb.2015.00021","article-title":"The immunoproteasome and viral infection: a complex regulator of inflammation","volume":"6","author":"McCarthy","year":"2015","journal-title":"Front Microbiol"},{"issue":"6","key":"2020081011342818600_B36","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1600-6143.2008.02242.x","article-title":"The number of activating KIR genes inversely correlates with the rate of CMV infection\/reactivation in kidney transplant recipients","volume":"8","author":"Stern","year":"2008","journal-title":"Am J Transplant"},{"issue":"8","key":"2020081011342818600_B37","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2010.02.024","article-title":"Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype","volume":"16","author":"Tomblyn","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020081011342818600_B38","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.bmt.1705468","article-title":"Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders","volume":"38","author":"Chen","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020081011342818600_B39","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1182\/blood-2005-03-1039","article-title":"Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation","volume":"107","author":"Cook","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2020081011342818600_B40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.bbmt.2008.11.030","article-title":"The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation","volume":"15","author":"Zaia","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020081011342818600_B41","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.leu.2403055","article-title":"Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia","volume":"17","author":"Kumar","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"2020081011342818600_B42","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2141.2004.04891.x","article-title":"Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation","volume":"125","author":"Kim","year":"2004","journal-title":"Br J Haematol"},{"issue":"4","key":"2020081011342818600_B43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ejh.12338","article-title":"Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts","volume":"93","author":"Michelis","year":"2014","journal-title":"Eur J Haematol"},{"issue":"12","key":"2020081011342818600_B44","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.3109\/10428194.2013.783912","article-title":"Early lymphocyte recovery predicts superior overall survival after unmanipulated haploidentical blood and marrow transplant for myelodysplastic syndrome and acute myeloid leukemia evolving from myelodysplastic syndrome","volume":"54","author":"Chang","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2020081011342818600_B45","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/bmt.2016.62","article-title":"Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation","volume":"51","author":"Solh","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/15\/3669\/1752333\/advancesadv2020001958.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/15\/3669\/1752333\/advancesadv2020001958.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T17:49:03Z","timestamp":1597081743000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/15\/3669\/461753\/Prospective-phase-2-trial-of-ixazomib-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":45,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001958","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]}}}